[go: up one dir, main page]

PE20091194A1 - Derivados de heterociclicos como moduladores del receptor m1 - Google Patents

Derivados de heterociclicos como moduladores del receptor m1

Info

Publication number
PE20091194A1
PE20091194A1 PE2008001632A PE2008001632A PE20091194A1 PE 20091194 A1 PE20091194 A1 PE 20091194A1 PE 2008001632 A PE2008001632 A PE 2008001632A PE 2008001632 A PE2008001632 A PE 2008001632A PE 20091194 A1 PE20091194 A1 PE 20091194A1
Authority
PE
Peru
Prior art keywords
methyl
alkyl
benzoxazole
piperidinyl
cyclohexyl
Prior art date
Application number
PE2008001632A
Other languages
English (en)
Inventor
David Gwyn Cooper
Ian Thomson Forbes
Vincenzo Garzya
Dale James Johnson
Graeme Irvine Stevenson
Paul Adrian Wyman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40029139&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091194(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0718419A external-priority patent/GB0718419D0/en
Priority claimed from GB0814902A external-priority patent/GB0814902D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20091194A1 publication Critical patent/PE20091194A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I), DONDE R4, R5 Y R6 SON CADA UNO H, HALOGENO, ALQUILO(C1-C6), ENTRE OTROS; EL ANILLO A ES BENCENO O UN ANILLO HETEROCICLICO DE 6 MIEMBROS; R ES CICLOALQUIL(C3-C6)-AQUILO(C1-C4), AQLUILOXI(C1-C6).ALQUILO(C1-C6), CICLOALQUILOXI(C3-C6)-ALQUILO(C1-C6), ENTRE OTROS; Q ES H Y ALQUILO (C1-C6); Y ES O, S, CF2, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 3-[1-TRANS-1-METIL-4{[2-(METILOXI)ETIL]OXI}CICLOHEXIL)-4-PIPERIDINIL]-2-OXO-2,3-DIHIDRO-1,3-BENZOXAZOL-5-CARBONITRILO, 5-METIL-3-[1-(TRANS-1-METIL-4{[2-(METOXI)ETIL]OXI}CICLOHEXIL)-4-PIPERIDINIL]-2-OXO-2,3-DIHIDRO-1,3-BENZOXAZOL-6-CARBONITRILO, 6-FLUORO-5-METIL-3-[1-(TRANS-1-METIL-4-{[2-(METILOXI)ETIL]OXI}CICLOHEXIL)-4-PIPERIDINIL]-1,3-BENZOXAZOL-2(3H)-ONA, ENTRE OTROS. SE REFIERE TAMBIEN A UN METODO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA QUE LOS COMPRENDE. LOS COMPUESTOS DE LA PRESENTE INVENCION SON MODULADORES DE LA ACTIVIDAD M1, POR LO QUE SON UTILES EN EL TRATMIENTO DEL DETERIORO COGNITIVO, TAL COMO LA ENFERMEDAD DE ALZHEIMER
PE2008001632A 2007-09-20 2008-09-18 Derivados de heterociclicos como moduladores del receptor m1 PE20091194A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0718419A GB0718419D0 (en) 2007-09-20 2007-09-20 Compounds
GB0814902A GB0814902D0 (en) 2008-08-14 2008-08-14 Compounds

Publications (1)

Publication Number Publication Date
PE20091194A1 true PE20091194A1 (es) 2009-09-05

Family

ID=40029139

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001632A PE20091194A1 (es) 2007-09-20 2008-09-18 Derivados de heterociclicos como moduladores del receptor m1

Country Status (9)

Country Link
US (1) US8299257B2 (es)
EP (1) EP2194983A1 (es)
JP (1) JP2010539218A (es)
AR (1) AR068480A1 (es)
CL (1) CL2008002808A1 (es)
PE (1) PE20091194A1 (es)
TW (1) TW200930367A (es)
UY (1) UY31346A1 (es)
WO (1) WO2009037296A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
FR2909090B1 (fr) * 2006-11-23 2009-01-09 Sanofi Aventis Sa Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique.
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
CN101663291A (zh) * 2007-04-23 2010-03-03 詹森药业有限公司 作为快速离解的多巴胺2受体拮抗剂的吡啶衍生物
JP5431305B2 (ja) * 2007-04-23 2014-03-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 高速解離性ドパミン２受容体アンタゴニストとしての４−アルコキシピリダジン誘導体
ES2400710T3 (es) * 2007-04-23 2013-04-11 Janssen Pharmaceutica, N.V. Tia(dia)zoles como antagonistas del receptor de dopamina 2 de disociación rápida
EP2194982A1 (en) * 2007-09-20 2010-06-16 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
ES2398625T3 (es) * 2008-07-03 2013-03-20 Janssen Pharmaceutica N.V. 6-(1-Piperazinil)-piritazinas sustituidas como antagonistas de receptores 5-HT6
CA2730774C (en) * 2008-07-31 2016-09-13 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
TWI841671B (zh) 2019-01-24 2024-05-11 日商第一三共股份有限公司 具有取代基之脲化合物
CN112812782B (zh) * 2021-01-21 2023-09-29 西安瑞联新材料股份有限公司 一种环己烷类苯并噁唑液晶化合物、制备方法及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU701127B2 (en) * 1994-10-27 1999-01-21 Merck & Co., Inc. Muscarine antagonists
WO1997016186A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine agonists
WO1999032481A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
US7087593B2 (en) * 2001-10-02 2006-08-08 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
JP5209479B2 (ja) 2005-09-30 2013-06-12 グラクソ グループ リミテッド Ｍ１受容体にて活性を有するベンゾイミダゾロン類
GB0605786D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
EP2194982A1 (en) * 2007-09-20 2010-06-16 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine

Also Published As

Publication number Publication date
TW200930367A (en) 2009-07-16
CL2008002808A1 (es) 2010-01-15
AR068480A1 (es) 2009-11-18
US8299257B2 (en) 2012-10-30
US20100210687A1 (en) 2010-08-19
UY31346A1 (es) 2009-04-30
WO2009037296A1 (en) 2009-03-26
JP2010539218A (ja) 2010-12-16
EP2194983A1 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
PE20091194A1 (es) Derivados de heterociclicos como moduladores del receptor m1
PE20091095A1 (es) Moduladores de gamma secretasa
AR066509A1 (es) Derivados de tiazol, medicamentos que los contienen, proceso de preparacion y usos como moduladores de beta amiloide.
PE20080730A1 (es) Derivados de fenilo como moduladores del receptor s1p
PE20120413A1 (es) ENANTIOMERO (S) DE 1'-{[5-(TRIFLUOROMETIL)FURAN-2-IL]METIL}ESPIRO[FURO[2,3-f][1,3]BENZODIOXOL-7,3'-INDOL]-2'(1'H)-ONA
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
PE20090729A1 (es) Moduladores de gamma-secretasa
AR060604A1 (es) Nuevos arilamino n- heteroarilos como inhibidores de mek
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
ECSP088863A (es) Compuestos que son agonistas de receptores muscarínicos y que pueden ser eficaces en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia
PE20081228A1 (es) Compuesto heteromonociclico
PE20090651A1 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3
PA8593101A1 (es) Composiciones para el tratamiento de crecimiento celular anormal
AR071609A1 (es) Inhibidores ciclicos de 11(beta) -hidroxiesteroide deshidrogenasa 1
PA8779901A1 (es) Compuestos amino-heterocíclicos
PE20120113A1 (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparacion y composiciones farmaceuticas que los contienen
AR071245A1 (es) Derivados de piperidina como antagonistas de receptores muscarinicos, procesos de obtencion y composiciones farmaceuticas
PE20060656A1 (es) COMPUESTOS DE IMIDAZO[1,2-a]PIRIDINIL COMO MODULADORES DE LA ACTIVIDAD DE QUIMIOQUINAS
AR061580A1 (es) Profarmacos de 5- amino-3-(3'- desoxi- beta-d - ribofuronosil)-tiazolo [4 ,5- d] pirimidin-2,7- diona
CO6382118A2 (es) Nuevas octahidrociclopenta(c)ciprol-4aminas sustituidas como bloqueantes de los canales de calcio
UY27752A1 (es) Derivados del tropano útiles en terapia
GT200700103A (es) Compuestos biciclocarboxiamida sustituidos
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
UY29412A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed